Skip to main content

Koselugo [SELUMETINIB] approved in the EU for plexiform neurofibromas in adults with neurofibromatosis type 1

Koselugo (Selumetinib) Approved in the EU for Plexiform Neurofibromas in Adults with Neurofibromatosis Type 1

Published on: November 2025 | By: ePharma Times

Pharmaceutical research lab

AstraZeneca and Merck & Co., Inc. have announced that Koselugo (selumetinib) has been granted marketing authorization in the European Union for the treatment of adults with Neurofibromatosis Type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PNs).

Why This Matters

Oncology treatment concept

NF1 is a rare genetic condition affecting around 1 in 3,000 people worldwide. These tumors can cause pain, disfigurement, and neurological complications. This EU approval marks a critical advancement in targeted therapy options for NF1, expanding treatment accessibility for adult patients across Europe.

Clinical and Patient Impact

Clinical research illustration

Clinical studies demonstrated that selumetinib led to meaningful tumor shrinkage and improved patient outcomes. By targeting the MEK pathway, Koselugo reduces tumor growth and enhances quality of life for individuals living with this complex disorder.

About Selumetinib

Selumetinib molecule structure

Selumetinib is a MEK 1/2 inhibitor developed through a strategic collaboration between AstraZeneca and Merck. It is also being investigated for multiple oncology indications, including thyroid and pediatric cancers.

Future Outlook

Future of oncology and innovation

With this EU approval, Koselugo strengthens its global footprint as a precision medicine designed to address rare tumor growths. Its success underscores the growing role of targeted therapies and intellectual property advancements in accelerating patient-centric innovation.

Related Reading

© 2025 ePharma Times | Source: AstraZeneca Press Release & EU Commission Database

Comments

Post a Comment

Popular posts from this blog

Transforming Healthcare: The Role of Artificial Intelligence in Pharmaceuticals and Medical Devices.

AI in Healthcare & Pharma: How Artificial Intelligence Is Transforming Drug Discovery and Medical Devices Artificial Intelligence (AI) is reshaping the global healthcare ecosystem. From drug discovery to diagnostics and patient care, AI has become the driving force behind the next wave of innovation in the pharmaceutical and medical device sectors. This article explores how AI technologies are transforming every stage of the healthcare value chain. AI in Pharmaceutical Development Accelerating Drug Discovery AI algorithms now analyze massive biological and chemical datasets to identify potential drug candidates in record time. Machine learning models predict molecular properties, toxicity levels, and drug–target interactions — drastically reducing preclinical failure rates. Major pharma companies are partnering with AI startups to shorten drug discovery timelines by up to 50%. Optimizing Clinical Trials AI supports patient selection, risk prediction, and real-time tr...
Post a Comment
Read more